235MO Efficacy and safety of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in younger patients (pts) with HR+/HER2− early breast cancer (EBC) in NATALEE
Year: 2024
Type: article
Source: Annals of Oncology
Authors: S. Loi, E. Stringer-reasor, J-S. Frenel, M. Reinisch, R. ORegan, M. De Laurentiis, Y.H. Park, A. O'Dea, Y-S. Lu, V. Gonzalez, M. Gao, S. Waters, H. Hu, B. Xu
Institutions: Peter MacCallum Cancer Centre, University of Alabama at Birmingham, O'Neal Comprehensive Cancer Center, Institut de Cancérologie de l'Ouest, Kliniken Essen-Mitte, University of Rochester Medicine, University of Rochester, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Samsung Medical Center, Sungkyunkwan University, University of Kansas Medical Center, National Taiwan University Hospital, Translational Research in Oncology, Novartis (Switzerland), Novartis (Ireland), Novartis (United States), Chinese Academy of Medical Sciences & Peking Union Medical College, Cancer Hospital of Chinese Academy of Medical Sciences
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4402561880